Anavex Life Sciences (AVXL) 3.69 $AVXL Anavex Confirms

New Post Public Reply Private Reply Replies (0) Message Board

Nov 17, 2015 at 1:49 PM

Anavex Life Sciences (AVXL) 3.69 $AVXL

Anavex Confirms Data for Phase 2a Alzheimer's Trial for ANAVEX 2-73
GlobeNewswire - Wed Nov 11, 6:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(Nasdaq:AVXL) confirms the information in the November 9, 2015 press release announcing positive safety and cognitive efficacy data from the Phase 2a Alzheimer's trial for ANAVEX 2-73.
AVXL: 3.69 (-0.53)

Stocks Bottom Out at Session Lows on Rate Hike Talk
at The Street - Mon Nov 09, 1:32PM CST
Stocks bottom out at session lows by mid-afternoon Monday as expectations over when the Federal Reserve might hike rates shift.
AMZN: 646.50 (-1.31), TSLA: 213.95 (-0.36), NSC: 87.08 (-1.22), KSU: 88.45 (+0.48), XLY: 79.00 (+0.33), PCL: 48.66 (+1.54), CSX: 27.41 (+0.10), PCLN: 1,258.74 (-8.13), NFLX: 116.94 (+5.59), AVXL: 3.69 (-0.53), WY: 30.95 (+0.81), APA: 49.94 (-0.55), COST: 159.59 (+3.14), CP: 138.63 (+1.24), DF: 18.36 (-0.05), UNP: 85.27 (+0.92)

Stocks Extend Losses as Priceline Leads Consumer Losers
at The Street - Mon Nov 09, 10:09AM CST
Stocks extend losses by mid-morning Monday as Priceline is a laggard in the consumer sector.
BID: 29.04 (-0.28), AMZN: 646.50 (-1.31), TSLA: 213.95 (-0.36), HTZ: 16.30 (+0.93), XLY: 79.00 (+0.33), PCL: 48.66 (+1.54), PCLN: 1,258.74 (-8.13), DISH: 62.23 (-0.22), NFLX: 116.94 (+5.59), ERIC: 9.48 (-0.06), AVXL: 3.69 (-0.53), WY: 30.95 (+0.81), APA: 49.94 (-0.55), COST: 159.59 (+3.14), DF: 18.36 (-0.05), CSCO: 26.98 (+0.19)

Penny Stocks Alerts for Invo Bioscience, Dominovas Energy, Medical Marijuana, Global Equity, TapImmune, and Anavex Life Sciences
PR Newswire - Mon Nov 09, 8:00AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Invo Bioscience (OTCMKTS:IVOB), Dominovas Energy (OTCMKTS

NRG), Medical Marijuana (OTCMKTS:MJNA), Global Equity (OTCBB:GEQU), TapImmune (OTCMKTS:TPIV), and Anavex Life Sciences (OTCMKTS:AVXL).
AVXL: 3.69 (-0.53)

Anavex Presents Meaningless Results in Alzheimer's Drug Study
at The Street - Mon Nov 09, 7:53AM CST
"The chance you would have gotten similar data giving the patients 10 cups of coffee a day instead? Almost 100%," said Dr. Adam Kline, a researcher who reviewed the data.
BIIB: 281.04 (-2.49), AVXL: 3.69 (-0.53)

Anavex Announces Positive Primary and Secondary Endpoints Were Achieved in a Phase 2a Clinical Trial of ANAVEX 2-73 in Alzheimer's Diseaseâ??
GlobeNewswire - Mon Nov 09, 6:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(Nasdaq:AVXL). On Saturday, investigators presented positive safety and cognitive efficacy data for ANAVEX 2-73, the Company's lead investigational oral treatment for Alzheimer's disease targeting sigma-1 and muscarinic receptors, which are believed to reduce protein misfolding including reduction of beta amyloid, tau protein and inflammation at the international CTAD 2015 conference in Barcelona, Spain.
AVXL: 3.69 (-0.53)

Anavex Announces CTAD 2015 Abstract
GlobeNewswire - Thu Nov 05, 2:13PM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, is pleased to announce that the abstract for its presentation of full PART A data and preliminary PART B data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 at the Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain on Saturday, November 7, 2015 is now available online.
AVXL: 3.69 (-0.53)

Why Anavex Life Sciences Shares Are Soaring 15% Today
Todd Campbell, The Motley Fool - Motley Fool - Mon Nov 02, 12:10PM CST
Image source: Avanex Life Sciences. What: After reporting last week that it has filed to uplist to the Nasdaq exchange and that it had inked a stock purchase deal with Lincoln Park Capital Fund, LLC worth up to $50 million, shares in Anavex Life...
AVXL: 3.69 (-0.53)

Penny Stocks Alerts for Urban Barns Foods, Buka Ventures, Hemp, GT Advanced Technologies, ANAVEX LIFE SCIENCES, and 3D EYE SOLUTIONS
PR Newswire - Mon Nov 02, 8:00AM CST
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Urban Barns Foods (OTCMKTS:URBF), Buka Ventures (OTCMKTS:NNRX), Hemp (OTCMKTS:HEMP), GT Advanced Technologies (OTCMKTS:GTATQ), ANAVEX LIFE SCIENCES (OTCMKTS:AVXLD), and 3D EYE SOLUTIONS (OTCMKTS:TDEY).
AVXL: 3.69 (-0.53)

Anavex Life Sciences Corp. (Nasdaq:AVXL) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Thu Oct 29, 9:00AM CDT
What:
AVXL: 3.69 (-0.53), NDAQ: 57.57 (+0.33)

Anavex Commences Trading on NASDAQ Today - To Ring Friday's Closing Bell
GlobeNewswire - Wed Oct 28, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, is pleased to announce that it will begin trading its common stock on the NASDAQ Capital Market today at the opening of market hours under the symbol "AVXL."
AVXL: 3.69 (-0.53)

Anavex Announces Uplisting to NASDAQ
GlobeNewswire - Mon Oct 26, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced the Company has received approval to begin trading its common stock on the NASDAQ Capital Market. Anavex's common stock will begin to trade on NASDAQ under the symbol "AVXL" at the opening of market hours on October 28, 2015.
AVXL: 3.69 (-0.53)

Military Researchers to Conduct Clinical Study of a "Skin Substitute" Using a Patient's Own Cells to Treat Complex Burns and Soft Tissue Injuries
PR Newswire - Tue Oct 13, 11:21AM CDT
Cooperative research and development efforts with the military, universities and the biotech industry can potentially lead to advancements in the treatment of severe wounds. Biotech companies with recent developments, partnerships and advancements in focus are Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), Array BioPharma, Inc. (NASDAQ: ARRY), Avanex Life Sciences Corp. (OTCQX: AVXLD), Juno Therapeutics, Inc. (NASDAQ: JUNO), and Progenix Pharmaceuticals, Inc. (NASDAQ: PGNX)
PGNX: 6.54 (-0.04), AVXL: 3.69 (-0.53), JUNO: 53.37 (-0.10), ARRY: 4.19 (-0.07)

Anavex to Present at 4th Annual OktoberINVESTfest Conference
GlobeNewswire - Mon Oct 12, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(OTCQX:AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 4th annual OktoberINVESTfest investors conference on Tuesday, October 13, 2015 at 2:30 p.m. ET. The Conference will be held at The New York Academy of Sciences in New York City.
AVXL: 3.69 (-0.53)

Anavex to Present Interim Phase 2a Clinical Trial Data of ANAVEX 2-73 at Late-Breaking Oral Session of CTAD 2015 Conference
GlobeNewswire - Wed Oct 07, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced the presentation of full PART A data and preliminary PART B data from the ongoing Phase 2a clinical trial of ANAVEX 2-73 at the upcoming Clinical Trials on Alzheimer's Disease (CTAD) conference in Barcelona, Spain from November 5-7, 2015. The late-breaking oral session will be presented by the trial's Principal Investigator, Stephen Macfarlane, FRANZCP, Director and Associate Professor, Aged Psychiatry at Caulfield Hospital in Melbourne, Australia.
AVXL: 3.69 (-0.53)

Anavex to announce uplisting to Nasdaq & reverse stock split
M2 - Wed Oct 07, 3:11AM CDT
Biopharmaceutical company Anavex Life Sciences (OtherOTC:AVXL) revealed on Tuesday that it has submitted and finalised its application for the uplisting of its common stock to the NASDAQ Capital Market.
AVXL: 3.69 (-0.53)

CORRECTING and REPLACING -- Anavex Prepares for Uplisting to NASDAQ, Announces Reverse Stock Split
GlobeNewswire - Tue Oct 06, 4:20PM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"

(OTCQX:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer's disease, other central nervous system (CNS) diseases, pain, and various types of cancer, today announced that it is finalizing an application to uplist trading of its common stock to the NASDAQ Capital Market. To meet the conditions of a NASDAQ listing, the Company announces a one-for-four (1-for-4) reverse stock split of its authorized, issued and outstanding common shares. The Company's common stock will begin trading on a post-split basis at the opening of trading on October 7, 2015.
AVXL: 3.69 (-0.53)

DUE DILIGENCE REPORT: Anavex Life Sciences Completes Enrollment for Clinical Phase 2a - BrokerBank Securities
PR Newswire - Tue Oct 06, 12:45PM CDT
Anavex Life Sciences Corp. (OTCQX: AVXL) shares closed at $1.90 yesterday, up 18.44%. Trading volume exceeded the 30 day average by a factor of three. The AVXL share price has been on a significant rise since July.
AVXL: 3.69 (-0.53)

Penny Stocks BUZZ for Hemp, Terra Tech, Medical Marijuana, NORTH AMERICAN CANNABIS HOLDINGS, Anavex Life Sciences, and Energizer Tennis
PR Newswire - Thu Oct 01, 8:00AM CDT
Pennystocksinsiders.com (PSI) released FREE insider trading reports for US market investors to track the following active stocks and penny stocks: Hemp (OTCMKTS:HEMP), Terra Tech (OTCMKTS:TRTC), Medical Marijuana (OTCMKTS:MJNA), NORTH AMERICAN CANNABIS HOLDINGS (OTCMKTS:USMJ), Anavex Life Sciences (OTCMKTS:AVXL), and Energizer Tennis (OTCBB:EZRT).
AVXL: 3.69 (-0.53)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2GenPen & LordCap Team Up: Game-Changer in ABS?

New Kids on the Structured Credit Block? Well, it looks like we're in for a ride with 2GenPen teaming up with Lord Capital to shake up the asset-backed securities (ABS) world. They're strutting their stuff by launching a strategic collaboration to boost credit analysis. Think of it as a power-up for ABS transactions—because nobody loves a murky credit rating. The Heart...

Florida Cancer Center Expands Expertise with New Oncologist

Welcoming a Highly Skilled Oncologist to Fort Myers There's an old saying in the world of investing: follow the expertise. And when it comes to healthcare, especially cancer treatment, expertise can make a world of difference. Florida Cancer Specialists & Research Institute (FCS) is throwing its hat in the ring with authority, as they welcome Dr. Kelly Elleson, a surgical...

Costa Rican Firms Chase Growth at SIAL Paris 2026

Chasing Growth in Paris: Costa Rica's Bold Move When it comes to playing the global field, Costa Rica isn't just sitting back; they're on the move. Picture this: PROCOMER, along with 18 standout companies, landed smack dab in the grand hustle and bustle of SIAL Paris 2026. This isn't some leisurely stroll—it's a calculated sprint toward expanding their reach across...

Alpha Rising Joins RFP: A Strong AI-Fueled Expansion

The Shift: From LPL to AI-Driven Innovation Hold onto your hats, because Alpha Rising Wealth Management has taken a significant leap from the traditional ship of LPL Financial to the cutting-edge shores of Rothschild Financial Partners (RFP). It's a move that's painting the walls in Scottsdale, Arizona with $250 million in client assets, all set to benefit from a modern,...

Tenet® Beef: Revolutionizing Tenderness in America's Steaks

Cracking the Code: A Genetic Leap in Beef Tenderness Well, buckle up, folks, because Callipyge Genetics is shaking things up in the beef aisle with their genomic breakthrough, Tenet®. It's about time we see some real innovation in an industry that's, let's face it, been slow to evolve. This isn't just a flash in the pan—a bit of DNA parsing has uncovered how to...

Navigating the Nitty-Gritty of Cabin Rental Management

The Real Elbow Grease Behind Cabin Management Ever imagined what it’d take to keep a vacation rental cabin running like a tight ship? Well, Nathan Fitts breaks it down real clear-like. The guy's seen it all in Blue Ridge, Georgia, which isn't just about scenic views—there's serious business brewing behind that cabin charm. More Than Just Fluffing Pillows Turns out,...

Cancer Memoir Shows Healing Beyond Medicine

Confronting the Unfathomable Out of the North Carolina mountains comes a story that defies expectations—a pastor and farmer named Mark Heisey, who faced the no-holds-barred trials of stage IV-B lymphoma. Now, I'll shoot you straight: this isn't your run-of-the-mill self-help guide or a clinical breakdown of battling cancer. His new memoir dives into the personal and...

Firmable's Tech Intelligence: New Edge in B2B Sales

New Era for B2B Sales Teams Once again, the B2B sales landscape is getting a jolt—especially for those who’ve been fumbling in the dark pitching to prospects without any real idea of their tech environment. With the introduction of Firmable's Tech Intelligence, those blind days just got a lot brighter. By offering detailed insights into what technologies a company is...

Endava Faces Securities Fraud Lawsuit: Investor Implications

Endava in Hot Water Over Alleged Misleading Statements Alright, folks, gather around—there's a storm brewing over at Endava with shareholders mightier than the Greek gods, furrowing their brows with intent. You see, Schall, Brown & Schwartz LLP, a firm that practically eats legal challenges for breakfast, is beating the drums of a securities fraud lawsuit. Yep, I'm...

DOCS Faces Investor Legal Battle for Alleged Misconduct

The DOCS Predicament: Investors Facing Class Action Doximity, Inc., trading as NYSE:DOCS, finds itself in hot water again as shareholders gear up for a legal skirmish over alleged securities fraud. Schall, Brown & Schwartz LLP, the firm rallying the shareholders, has fired the opening salvo, pointing fingers at Doximity for cooking the books about their Newsfeed’s...